PE20060358A1 - Cristal estable del compuesto 4-oxoquinolina - Google Patents

Cristal estable del compuesto 4-oxoquinolina

Info

Publication number
PE20060358A1
PE20060358A1 PE2005000561A PE2005000561A PE20060358A1 PE 20060358 A1 PE20060358 A1 PE 20060358A1 PE 2005000561 A PE2005000561 A PE 2005000561A PE 2005000561 A PE2005000561 A PE 2005000561A PE 20060358 A1 PE20060358 A1 PE 20060358A1
Authority
PE
Peru
Prior art keywords
crystal
stable crystal
oxoquinoline compound
diffration
forms
Prior art date
Application number
PE2005000561A
Other languages
English (en)
Spanish (es)
Inventor
Motohide Satoh
Takahisa Motomura
Kentaro Kondo
Koji Matsuda
Hideto Uehara
Shuji Miyake
Koji Ando
Takashi Matsuda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20060358A1 publication Critical patent/PE20060358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
PE2005000561A 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina PE20060358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
PE20060358A1 true PE20060358A1 (es) 2006-05-12

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005000561A PE20060358A1 (es) 2004-05-20 2005-05-20 Cristal estable del compuesto 4-oxoquinolina
PE2011002129A PE20120361A1 (es) 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011002129A PE20120361A1 (es) 2004-05-20 2005-05-20 Composiciones farmaceuticas que comprenden formas cristalinas de acido 6-(3-cloro-2-fluorobencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolina-3-carboxilico

Country Status (33)

Country Link
US (7) US7635704B2 (enExample)
EP (4) EP3281939B1 (enExample)
JP (1) JP3754064B2 (enExample)
KR (1) KR20080064909A (enExample)
CN (1) CN1956961B (enExample)
AR (2) AR049280A1 (enExample)
AU (1) AU2005245296B2 (enExample)
BE (1) BE2024C511I2 (enExample)
BR (1) BRPI0510114B8 (enExample)
CA (1) CA2566922C (enExample)
CY (4) CY1113010T1 (enExample)
DK (2) DK3281939T3 (enExample)
ES (2) ES2388441T3 (enExample)
FI (2) FI3281939T3 (enExample)
FR (1) FR23C1040I1 (enExample)
HR (2) HRP20120681T1 (enExample)
HU (2) HUE064615T2 (enExample)
IL (1) IL179250A0 (enExample)
LT (2) LT3281939T (enExample)
LU (1) LUC00334I2 (enExample)
MX (1) MXPA06013405A (enExample)
MY (1) MY134672A (enExample)
NO (8) NO339223B1 (enExample)
NZ (1) NZ551839A (enExample)
PE (2) PE20060358A1 (enExample)
PL (2) PL1636190T3 (enExample)
PT (2) PT3281939T (enExample)
RS (2) RS52375B (enExample)
RU (1) RU2330845C1 (enExample)
SI (2) SI1636190T1 (enExample)
TW (1) TWI329015B (enExample)
WO (1) WO2005113508A1 (enExample)
ZA (1) ZA200610647B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
WO2004046115A1 (ja) * 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
BRPI0620865A2 (pt) 2005-12-30 2011-11-29 Gilead Sciences Inc métodos para melhorar a farmacocinética de inibidores das integrases do hiv
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
KR101023635B1 (ko) 2006-03-06 2011-03-22 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 제조 방법
IN2014CN00532A (enExample) 2006-03-06 2015-04-03 Japan Tobacco Inc
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
BRPI0716752A2 (pt) 2006-09-12 2013-09-17 Gilead Sciences Inc processo e intermediÁrios para preparo de inibidores de intergrase
EP4403221A3 (en) * 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
BRPI0813955A2 (pt) * 2007-06-29 2017-05-09 Gilead Sciences Inc composições terapêuticas e o uso das mesmas
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
CN103479584A (zh) 2008-05-02 2014-01-01 吉里德科学公司 固体载体颗粒在改善药物制剂加工性中的应用
CN102307573B (zh) 2009-02-06 2013-09-11 吉里德科学公司 用于联合治疗的片剂
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
NZ630199A (en) 2012-08-03 2016-12-23 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
NO2865735T3 (enExample) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536B1 (en) * 2020-10-19 2025-06-25 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (enExample) 1970-09-14 1981-02-16
JPS4826772A (enExample) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
CA2194435A1 (en) 1994-07-18 1996-02-01 Ube Industries, Ltd. Trifluoromethylquinolinecarboxylic acid derivative
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
DE69709857T2 (de) 1996-04-12 2002-08-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Acridonderivate als antineoplastische-und antiretrovirale mittel
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE60124577T2 (de) 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
IL157638A0 (en) 2001-03-01 2004-03-28 Shionogi & Co Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
RU2206564C1 (ru) * 2002-03-07 2003-06-20 Общество с ограниченной ответственностью "Поливит" Способ получения этилового эфира 6-фтор-7-хлор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
WO2004046115A1 (ja) * 2002-11-20 2004-06-03 Japan Tobacco Inc. ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2229945A1 (en) 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents

Also Published As

Publication number Publication date
BRPI0510114B8 (pt) 2021-05-25
CY2015009I1 (el) 2024-09-20
HRP20231588T3 (hr) 2024-03-15
CY2024008I1 (el) 2024-09-20
LTPA2024001I1 (enExample) 2024-04-10
NO20230913A1 (no) 2007-02-07
TWI329015B (en) 2010-08-21
SI3281939T1 (sl) 2024-02-29
RU2330845C1 (ru) 2008-08-10
US20220235009A1 (en) 2022-07-28
ZA200610647B (en) 2008-06-25
AR096100A2 (es) 2015-12-09
EP1636190B1 (en) 2012-06-27
ES2388441T3 (es) 2012-10-15
FI3281939T3 (fi) 2023-10-23
IL179250A0 (en) 2007-03-08
NO2024034I1 (no) 2024-07-15
CY2024008I2 (el) 2024-09-20
CA2566922A1 (en) 2005-12-01
DK1636190T3 (da) 2012-09-24
BE2024C511I2 (enExample) 2024-10-08
BRPI0510114B1 (pt) 2020-09-15
NO20200873A1 (no) 2007-02-07
JP2006001927A (ja) 2006-01-05
LUC00334I2 (enExample) 2024-07-01
US20150361044A1 (en) 2015-12-17
CN1956961B (zh) 2010-05-26
TW200600097A (en) 2006-01-01
EP2514746A1 (en) 2012-10-24
NZ551839A (en) 2009-11-27
NO20190051A1 (no) 2007-02-07
LTC3281939I2 (enExample) 2025-04-25
NO20161297A1 (no) 2007-02-07
HUE064615T2 (hu) 2024-04-28
CY1113010T1 (el) 2016-04-13
PT3281939T (pt) 2023-11-22
US8981103B2 (en) 2015-03-17
SI1636190T1 (sl) 2012-09-28
NO339223B1 (no) 2016-11-21
MY134672A (en) 2007-12-31
NO20065790L (no) 2007-02-07
CN1956961A (zh) 2007-05-02
NO347902B1 (no) 2024-05-06
CY2015009I2 (el) 2024-09-20
ES2960824T3 (es) 2024-03-06
AR049280A1 (es) 2006-07-12
EP1636190A1 (en) 2006-03-22
FIC20240008I1 (fi) 2024-03-20
US20250091995A1 (en) 2025-03-20
HK1083341A1 (en) 2006-06-30
RS64845B1 (sr) 2023-12-29
AU2005245296A1 (en) 2005-12-01
EP3281939B1 (en) 2023-10-18
LT3281939T (lt) 2023-11-27
PE20120361A1 (es) 2012-05-03
US20060030710A1 (en) 2006-02-09
CY1126560T1 (el) 2024-09-20
RS52375B (sr) 2012-12-31
US20190185433A1 (en) 2019-06-20
FR23C1040I1 (fr) 2023-12-29
PL3281939T3 (pl) 2024-03-18
AU2005245296B2 (en) 2010-08-12
PT1636190E (pt) 2012-08-20
HUS2400006I1 (hu) 2024-04-28
MXPA06013405A (es) 2007-03-01
US20100204271A1 (en) 2010-08-12
EP4299563A2 (en) 2024-01-03
US20180029989A1 (en) 2018-02-01
WO2005113508A1 (en) 2005-12-01
EP3281939A1 (en) 2018-02-14
DK3281939T3 (da) 2024-01-22
BRPI0510114A (pt) 2007-09-25
KR20080064909A (ko) 2008-07-09
NO20220690A1 (no) 2007-02-07
JP3754064B2 (ja) 2006-03-08
HRP20120681T1 (hr) 2012-09-30
PL1636190T3 (pl) 2012-10-31
CA2566922C (en) 2011-01-11
NO20240384A1 (no) 2007-02-07
EP4299563A3 (en) 2024-02-28
US7635704B2 (en) 2009-12-22

Similar Documents

Publication Publication Date Title
UY38793A (es) Compuestos químicos
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
UY28760A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
ATE483707T1 (de) 2-cyclopropylthiazolderivate
BR112013004220A2 (pt) fenilamidinas tendo uma atividade fungicida alta e seu uso.
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
MX375507B (es) Uso de derivados del ácido tetrámico como nematicidas.
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
DOP2009000227A (es) Derivados de aril isoxazolina insecticidas
CL2015002606A1 (es) Compuesto.
ECSP12012042A (es) Derivados de pirazol como inhibidores de jak
MX2012006964A (es) Nuevos antagonistas del receptor ccr2 y usos de los mismos.
CU23944B1 (es) Amidas del ácido pirrolidin-1,2-dicarboxílico sustituidas como moduladores de calicreína 7
EA201170703A1 (ru) Производные адамантилбензамида
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
SE0800742L (sv) Vikttäcke
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
EA201891804A1 (ru) Тетрациклиновые соединения

Legal Events

Date Code Title Description
FG Grant, registration